@misc{10481/80548,
year = {2023},
month = {2},
url = {https://hdl.handle.net/10481/80548},
abstract = {Introduction: Hidradenitis suppurativa (HS)
has been linked to higher cardiovascular risk
(CVR) due to its inflammatory burden. There is
little evidence on how biologic treatment could
modify the cardiovascular risk of patients with
HS. The aims of the present study were to
explore the modification of CVR in patients
under adalimumab treatment and to explore
the potential factors associated with CVR
improvement.
Methods: A prospective longitudinal study was
performed. A cohort of patients with HS treated
with adalimumab was followed up. Carotid
intima–media thickness (IMT) and other
clinical and biochemical CVR factors were collected
at baseline and 32 weeks after starting the
treatment.
Results: Twenty-seven patients with severe HS
were included. Overall, there were no differences
in IMT between baseline (633 lm) and
32 weeks follow-up (634 lm). However, 40.7%
(11/27) of the patients presented an improvement
in IMT. This group (IMT responders) had a
higher prevalence of dyslipidemia, diabetes
mellitus, higher HbA1c levels, consumed more
tobacco, and had higher BMI at baseline.
Moreover, these patients had lower IHS4 scores
at baseline and tended to have a greater IMT
basal value, indicating a higher burden of subclinical
atherosclerosis.
Conclusions: Adalimumab treatment might
benefit a subset of patients with HS in terms of
cardiovascular risk reduction. In light of the
results of the present study patients with classical
cardiovascular risk factors, and those with
higher burden of subclinical atherosclerosis and
with less inflammatory load, may be more likely
to improve their IMT during adalimumab
treatment.},
publisher = {Springer},
keywords = {Cardiovascular risk},
keywords = {Anti-TNF therapy},
keywords = {Adalimumab},
keywords = {Hidradenitis suppurativa},
keywords = {Ultrasonography},
title = {Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima– Media Thickness Reduction},
doi = {10.1007/s13555-023-00898-z},
author = {Sánchez Díaz, Manuel and Salvador Rodríguez, Luis and Cuenca Barrales, Carlos and Arias Santiago, Salvador Antonio},
}